Literature DB >> 28011005

The enduring patency of primary inferior vena cava repair.

Neel A Mansukhani1, George E Havelka1, Irene B Helenowski2, Heron E Rodriguez1, Andrew W Hoel1, Mark K Eskandari3.   

Abstract

BACKGROUND: Inferior vena cava repair after planned and unplanned venotomy is performed by either interposition bypass, patch venopasty, or lateral venorrhaphy and primary repair. Primary repair of the inferior vena cava avoids the use of foreign material and allows an all-autologous repair in an expeditious fashion. The purpose of this study was to demonstrate the utility of inferior vena cava repair, determine the degree of inferior vena cava stenosis, and examine clinical outcomes after primary repair.
METHODS: We conducted a single-center retrospective review of patients who underwent primary inferior vena cava repairs between January 2002 and January 2014 at a tertiary care center. Primary repair followed lateral venorrhaphy for tumor extraction or for repair of an iatrogenic inferior vena cava injury. Patient demographics, cross-sectional vena cava dimensions, and patient outcomes were tabulated.
RESULTS: In total, 47 (30 men and 17 women) patients underwent primary inferior vena cava repair (median age 58 years, range 31-83 years). Twenty-six patients (15 men and 11 women) underwent en bloc radical nephrectomy, inferior vena cava tumor thrombus extraction, and primary lateral venorrhaphy (median age 61 years, range 39-83 years). The majority, 92% of these patients, had renal cell carcinoma on final pathology, with a median follow-up period of 39 months (range 1-108 months). Twenty-one patients (15 men and 6 women) underwent primary repair for iatrogenic inferior vena cava injury (median age 54 years, range 31-82 years). The median follow-up period was 18.5 months (3-110 months). Clinic follow-up with postoperative imaging was obtained in 76.9% of those undergoing tumor thrombus extraction (n = 20) and 76.2% of those undergoing repair of an iatrogenic injury (n = 16). Overall, there was a 13% infrarenal inferior vena cava diameter loss, 17% inferior vena cava diameter loss at the level of the renal veins, and 10% suprarenal inferior vena cava diameter loss when comparing postoperative with preoperative imaging. All patients remained asymptomatic; therefore, inferior vena cava narrowing associated with primary repair was clinically insignificant.
CONCLUSION: Primary inferior vena cava repair is associated with less than 20% inferior vena cava diameter loss and does not compromise venous outflow from the extremities. Primary inferior vena cava repair is a safe and expeditious technique that provides excellent clinical outcomes and long-term patency.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 28011005      PMCID: PMC5404996          DOI: 10.1016/j.surg.2016.11.006

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  32 in total

1.  Renal cell carcinoma associated with tumor thrombus in the inferior vena cava: surgical strategies.

Authors:  Laurent Zini; Stéphan Haulon; Christophe Decoene; Nordine Amara; Arnauld Villers; Jacques Biserte; Xavier Leroy; Mohamed Koussa
Journal:  Ann Vasc Surg       Date:  2005-07       Impact factor: 1.466

2.  The use of bovine pericardium for complex urologic venous reconstruction.

Authors:  Sarah Coleman; Hannah Kerr; Venkatesh Krishnamurthi; Alvin Wee; Michael Gong; Islam Ghoneim; John C Rabets
Journal:  Urology       Date:  2013-11-22       Impact factor: 2.649

3.  Total prosthetic transplantation of the inferior vena cava, with venous drainage restoration of the one remaining kidney on the graft, successfully performed on a child with Wilms' tumor.

Authors:  L Sarti
Journal:  Surgery       Date:  1970-05       Impact factor: 3.982

Review 4.  Resection of primary leiomyosarcoma of the inferior vena cava (IVC) with reconstruction: a case series and review of the literature.

Authors:  Heather Wachtel; Benjamin M Jackson; Edmund K Bartlett; Giorgos C Karakousis; Robert E Roses; Joseph E Bavaria; Douglas L Fraker
Journal:  J Surg Oncol       Date:  2014-10-08       Impact factor: 3.454

Review 5.  EAU guidelines on renal cell carcinoma: 2014 update.

Authors:  Borje Ljungberg; Karim Bensalah; Steven Canfield; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Peter Mulders; Thomas Powles; Michael Staehler; Alessandro Volpe; Axel Bex
Journal:  Eur Urol       Date:  2015-01-21       Impact factor: 20.096

6.  Outcome of iatrogenic injuries to the abdominal and pelvic veins.

Authors:  Tommaso Mandolfino; Aldo Canciglia; Filippo Taranto; Mario D'Alfonso; Agata Tonante; Marcello Mamo; Giovanni Sturniolo
Journal:  Surg Today       Date:  2008-10-29       Impact factor: 2.549

7.  Surgical resection and inferior vena cava reconstruction for treatment of the malignant tumor: technical success and outcomes.

Authors:  Hitoshi Goto; Munetaka Hashimoto; Daijiro Akamatsu; Takuya Shimizu; Noriyuki Miyama; Ken Tsuchida; Yuta Tajima; Noriaki Ohuchi
Journal:  Ann Vasc Dis       Date:  2014-03-15

8.  Single-center experience of caval thrombectomy in patients with renal cell carcinoma with tumor thrombus extension into the inferior vena cava.

Authors:  Grace J Wang; Jeffrey P Carpenter; Ronald M Fairman; Benjamin M Jackson; Bruce Malkowicz; Keith N Van Arsdalen; Edward Y Woo
Journal:  Vasc Endovascular Surg       Date:  2008-07-11       Impact factor: 1.089

9.  Fifteen-year experience with renal cell carcinoma with associated venous tumor thrombus.

Authors:  Michael J Nooromid; Mila H Ju; George E Havelka; James M Kozlowski; Shilajit D Kundu; Mark K Eskandari
Journal:  Surgery       Date:  2016-08-06       Impact factor: 3.982

10.  Resection of the inferior vena cava for urological malignancies: single-center experience.

Authors:  Shuichi Kato; Toshiaki Tanaka; Hiroshi Kitamura; Naoya Masumori; Toshiro Ito; Nobuyoshi Kawaharada; Taiji Tsukamoto
Journal:  Int J Clin Oncol       Date:  2012-09-06       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.